BioMarin Pharmaceutical (BMRN) updated its full year 2026 guidance after second quarter results that included revenue of US$989.71 million and new contributions from the Amicus acquisition, drawing fresh attention to the stock.

At a share price of US$68.53, BioMarin Pharmaceutical has seen strong short term momentum, with the 7 day share price return of 11.5% and 90 day share price return of 32.27%, while the 3 year total shareholder return is still down 23.34%. This shows that the recent strength is emerging from a weaker longer term base and likely reflects shifting expectations after the Amicus acquisition, updated 2026 guidance and the upcoming appearance at the Canaccord Genuity growth conference.

If you are tracking how biotech news can quickly reset expectations, it can also be useful to see what is moving outside large caps and review 44 healthcare AI stocks

BioMarin Pharmaceutical now looks more like a scaled rare disease platform than a niche biotech after the Amicus deal and guidance reset. The real question is whether that higher quality profile is already in the price.

Most Popular Narrative: 22% Undervalued

BioMarin Pharmaceutical's most followed narrative pegs fair value at $87.85 compared with the latest close of $68.53, framing the move after guidance and the Amicus deal as a valuation gap rather than just a momentum bounce.

Strong year-over-year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top-line revenue growth.

Want to see what sits behind that projected step up in revenue, earnings power and margins? One set of growth, profitability and discount rate assumptions does the heavy lifting. Curious how much future profitability this narrative needs to justify that higher fair value? The full breakdown shows exactly how those moving pieces fit together.

Result: Fair Value of $87.85 (UNDERVALUED)

However, BioMarin Pharmaceutical still carries key risks, including heavier reliance on VOXZOGO and uncertainty around BMN 401 after the mixed Phase 3 ENPP1 deficiency data.

Next Steps

If this mix of optimism and concern around BioMarin Pharmaceutical feels familiar, that is the point. Use the latest data, test the assumptions, and weigh both sides by checking the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond BioMarin Pharmaceutical?

Do not stop with BioMarin Pharmaceutical. Use the same structured approach to scan wider opportunities and spot stocks that better match your risk tolerance and goals.

• Target potential bargains by reviewing the 51 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their financial profile.
• Strengthen your core holdings by assessing companies in the solid balance sheet and fundamentals stocks screener (49 results) that pair healthier finances with more resilient business models.
• Get ahead of the crowd by checking the screener containing 18 high quality undiscovered gems before other investors start paying closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.